查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2075012

神經發育篩檢技術市場預測至2034年—按篩檢類型、組件、技術、應用、最終用戶和地區分類的全球分析

Neurodevelopmental Screening Technologies Market Forecasts to 2034 - Global Analysis By Screening Type, Component, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球神經發育篩檢技術市場規模將達到 17 億美元，並在預測期內以 8.2% 的複合年成長率成長，到 2034 年將達到 32 億美元。

神經發育篩檢技術是用於識別兒童和青少年認知、行為、語言和運動發展異常模式的診斷和評估工具。這些技術包括標準化評估工具、人工智慧驅動的數位篩檢工具、神經影像平台和行為觀察系統，臨床醫生和教育工作者利用這些技術來檢測泛自閉症障礙、注意力不足/過動症（ADHD）、發育遲緩和學習障礙等疾病。篩檢結果指南制定針對受影響個體的早期療育計畫和治療方案。

強制性早期療育正在推動成長。

隨著科學共識的不斷加深，早期識別神經發育障礙並及時治療性介入已證實能顯著改善兒童的長期預後。已開發國家的公共衛生計畫現已強制要求在兒童發展的特定里程碑階段進行普遍的發展篩檢，從而對標準化篩檢工具產生了系統性的需求。教育領域的融合政策要求學校識別並為存在神經發育差異的學生提供適當的支持。家長對發育篩檢的認知度也顯著提高，導致就診量增加。這些結構性政策和趨勢正在推動機構採購更多檢驗的篩檢技術。

專業人員短缺

準確的神經發育評估需要訓練有素的臨床專業人員，例如發育小兒科、兒童心理學家和語言病理學家，但全球專業人員的供給與篩檢需求相比仍然嚴重不足。公共醫療系統中漫長的診斷等待時間延誤了已確診問題的兒童的干預，並限制了篩檢計畫的有效效果。農村和醫療服務不足地區的人們面臨嚴重的就醫障礙，這限制了科技的應用機會。進行標準化評估所需的訓練要求對資源有限的醫療系統而言構成營運限制。儘管市場需求強勁，但這些人力資源瓶頸阻礙了市場擴張。

人工智慧遠端篩檢

人工智慧 (AI) 和電腦視覺技術正在推動遠端、半自動化神經發育篩檢應用的發展，使其不再局限於專業診所。利用影片分析演算法的行動應用可以評估家庭環境中的社交注意力和溝通模式，從而使更廣泛的公眾能夠獲得初步篩檢的機會。對數位生物標記的研究正在幫助人們識別可透過消費級設備檢測的可測量生理和行為指標。與遠端醫療平台的整合使得專家能夠遠端查看 AI 產生的篩檢結果。這些創新解決了目前限制篩檢項目擴充性的地域和人力資源障礙。

還款政策的差異

由於不同保險類別和國家醫療保健系統對神經發育篩檢的報銷政策各不相同，技術供應商和臨床醫生的收入前景充滿不確定性。許多人工智慧驅動的數位篩檢工具缺乏既定的報銷代碼，限制了它們在計量型。在某些市場，公共保險機構的預算限制也限制了新篩檢方法的推廣。此外，不同司法管轄區對診斷軟體的法規核准流程也存在差異，這使得進入國際市場變得更加複雜。即使某些技術的臨床效用已被證實且擁有強力的證據基礎，這些報銷障礙仍然阻礙了其廣泛應用。

新型冠狀病毒（COVID-19）的影響：

新冠疫情導致小兒科常規就診延後，造成全球發展篩檢計畫中斷，大量兒童篩檢。學校停課使教師難以辨識兒童發展問題，延誤了轉診至專科醫生。疫情後，隨著人們意識到封鎖期間早期社交活動減少與發育遲緩的關聯性增強，對篩檢的需求也隨之增加。疫情期間遠端醫療的普及加速了遠距篩檢方法的應用，並為數位化評估技術的實施建立了永續的基礎設施。

在預測期內，自閉症篩檢領域預計將佔據最大的市場佔有率。

預計在預測期內，自閉症篩檢領域將佔據最大的市場佔有率，這主要得益於泛自閉症障礙在全球範圍內的高發病率以及各國機構對早期篩檢計畫的大量投入。自閉症篩檢工具是神經發育評估領域中商業性化程度最高、臨床檢驗的細分市場。美國和一些歐洲國家強制推行自閉症篩檢，確保了篩檢工具的穩定供應。大量的研究投入催生了眾多適用於不同臨床環境的、檢驗的篩檢工具。醫療保健系統對自閉症早期篩檢的重視，也支撐了對篩檢技術的持續需求。

預計在預測期內，軟體領域將呈現最高的複合年成長率。

在預測期內，軟體產業預計將呈現最高的成長率，這主要得益於人工智慧驅動的評估平台的快速發展，這些平台顯著提升了篩檢的效率和準確性，超越了傳統的紙本檢測工具。雲端軟體平台能夠實現檢驗的評估內容和基準值資料庫的無縫更新。與電子健康記錄系統的整合支援了臨床工作流程的整合和結果追蹤。訂閱式交付模式降低了診所實施的資本投入門檻。針對不同文化和語言背景人群的、檢驗的、循證的數位化評估工具的日益普及，正在擴大目標臨床市場。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這主要得益於美國各州醫療系統中已建立的、普遍適用的新生兒和兒童發展篩檢計畫。美國疾病管制與預防中心 (CDC) 制定了全面的自閉症篩檢指南，並在兒童實踐中得到應用。由專業兒童醫院、發育小兒科診所和早期療育服務機構組成的緊密網路，為技術的廣泛應用提供了有力支持。 Cognoa、BrainCheck 和 Qbtech 等領先供應商在北美擁有強大的商業性影響力。聯邦和州政府對早期療育的資助，也為可靠的報銷體系提供了保障。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於兒童醫療基礎設施的快速擴張以及各國政府對神經發育篩檢計畫的大力投入。在中國和印度，自閉症和發展障礙的國家框架正在逐步建立，從而催生了對大規模篩檢計畫的需求。澳洲的國家殘障人士保險計畫（NDIS）為早期療育服務提供資金，前提是必須獲得正式診斷，這也促進了篩檢數量的成長。日本的綜合性婦幼保健計劃在兒童發展階段的多個里程碑節點納入了發育評估。中產階級父母對發展障礙的日益關注，也推動了私部門需求的強勁成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性評估）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球神經發育篩檢技術市場：依篩檢類型分類

  • 自閉症篩檢
  • ADHD篩檢
  • 發展遲緩篩檢
  • 語言和溝通評估
  • 學習障礙篩檢
  • 認知功能篩檢

第6章 全球神經發育篩檢技術市場：依組件分類

  • 軟體
  • 硬體
  • 診斷設備
  • 分析平台
  • 服務
  • 評估資料庫

第7章 全球神經發育篩檢技術市場：依技術分類

  • 人工智慧驅動的篩檢平台
  • 數位評估工具
  • 神經影像技術
  • 行為分析系統
  • 行動篩檢應用程式
  • 認知評估平台
  • 遠端醫療篩檢技術

第8章 全球神經發育篩檢技術市場：依應用分類

  • 兒童醫學
  • 教育評估
  • 早期療育計劃
  • 研究與學習
  • 社區健康篩檢
  • 遠端醫療服務
  • 臨床診斷

第9章 全球神經發育篩檢技術市場：依最終用戶分類

  • 醫院
  • 診所
  • 教育機構
  • 研究中心
  • 政府機構
  • 當地衛生組織

第10章 全球神經發育篩檢技術市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Medtronic plc
  • Philips Healthcare
  • GE HealthCare
  • Siemens Healthineers AG
  • Roche Diagnostics
  • Cognoa, Inc.
  • Qbtech AB
  • Pearson plc
  • Riverside Insights
  • BrainCheck Inc.
  • Neurotech International
  • Natus Medical Incorporated
  • Canon Medical Systems
  • Fujifilm Holdings Corporation
  • IBM Corporation
  • Oracle Health
  • Epic Systems Corporation
  • Koninklijke KPN NV
Product Code: SMRC37519

According to Stratistics MRC, the Global Neurodevelopmental Screening Technologies Market is accounted for $1.7 billion in 2026 and is expected to reach $3.2 billion by 2034 growing at a CAGR of 8.2% during the forecast period. Neurodevelopmental screening technologies are diagnostic and assessment instruments designed to identify atypical cognitive, behavioral, linguistic, and motor development patterns in pediatric and adolescent populations. These technologies encompass standardized assessment batteries, AI-assisted digital screening tools, neuroimaging platforms, and behavioral observation systems that clinicians and educators use to detect conditions including autism spectrum disorder, attention deficit hyperactivity disorder, developmental delays, and learning disabilities. Outputs guide early intervention planning and therapeutic program design for affected individuals.

Market Dynamics:

Driver:

Early intervention mandate growth

Growing scientific consensus confirms that early identification of neurodevelopmental conditions significantly improves long-term outcomes for affected children through timely therapeutic interventions. National public health programs in developed economies now mandate universal developmental screening at defined pediatric milestones, creating systematic demand for standardized screening tools. Educational inclusion policies require schools to identify and accommodate students with neurodevelopmental differences. Parent awareness of developmental screening has increased substantially, driving clinical visit volume. These structural policies and behavioral trends expand institutional procurement of validated screening technologies.

Restraint:

Specialist workforce shortages

Accurate neurodevelopmental assessment requires trained clinical specialists, including developmental pediatricians, child psychologists, and speech-language pathologists, whose global supply remains critically inadequate relative to screening demand. Long diagnostic wait times in publicly funded healthcare systems delay intervention for identified children, limiting the practical impact of screening programs. Rural and underserved populations face acute access deficits that restrict technology deployment opportunities. Training requirements for standardized assessment administration create operational constraints for resource-limited health systems. These workforce bottlenecks suppress market expansion despite strong underlying demand.

Opportunity:

AI-powered remote screening

Artificial intelligence and computer vision technologies are enabling remote and semi-automated neurodevelopmental screening applications that extend reach beyond specialist clinic settings. Mobile applications using video analysis algorithms can assess social attention and communication patterns in home environments, democratizing access to preliminary screening. Digital biomarker research advances identification of measurable physiological and behavioral indicators detectable through consumer devices. Telehealth platform integration allows remote specialist review of AI-generated screening outputs. These technological innovations address geographic and workforce access barriers that currently constrain screening program scalability.

Threat:

Reimbursement policy fragmentation

Variable reimbursement policies for neurodevelopmental screening across insurance categories and national health systems create uncertain revenue environments for technology vendors and clinical providers. Many AI-powered digital screening tools lack established reimbursement codes, limiting their adoption in fee-for-service healthcare models. Public payer budget constraints in several markets restrict coverage expansions for newer screening modalities. The heterogeneous regulatory approval pathways for diagnostic software across jurisdictions complicate international market entry. These reimbursement barriers slow technology diffusion despite demonstrated clinical utility and strong evidence bases.

Covid-19 Impact:

The COVID-19 pandemic disrupted developmental screening programs globally as routine pediatric appointments were deferred, creating a significant backlog of unscreened children. School closures impaired teacher identification of developmental concerns, delaying referrals. Post-pandemic, recognition of elevated developmental delays linked to reduced early socialization during lockdowns intensified screening demand. Telehealth expansion during the pandemic accelerated acceptance of remote screening modalities, creating sustainable infrastructure for digital assessment technology adoption.

The autism screening segment is expected to be the largest during the forecast period

The autism screening segment is expected to account for the largest market share during the forecast period, due to the high global prevalence of autism spectrum disorder and extensive institutional investment in early identification programs. Autism screening tools represent the most commercially developed and clinically validated segment within neurodevelopmental assessment. National autism screening mandates in the United States and several European countries generate consistent procurement volume. Substantial research investment has produced multiple validated screening instruments suitable for diverse clinical settings. Healthcare system prioritization of early autism identification underpins sustained demand for screening technology.

The software segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the software segment is predicted to witness the highest growth rate, driven by the rapid development of AI-powered assessment platforms that enhance screening efficiency and accuracy beyond traditional paper-based instruments. Cloud-hosted software platforms enable seamless updates with validated assessment content and normative databases. Integration with electronic health record systems supports clinical workflow embedding and outcome tracking. Subscription delivery models reduce capital expenditure barriers for clinic adoption. Increasing availability of evidence-based digital assessment tools validated for diverse cultural and linguistic populations expands the addressable clinical market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to well-established universal newborn and pediatric developmental screening programs mandated across the United States state health systems. The United States Centers for Disease Control maintains comprehensive autism screening guidelines implemented across pediatric practices. A dense network of specialist children's hospitals, developmental pediatric clinics, and early intervention service providers sustains robust technology procurement. Major vendors, including Cognoa, BrainCheck, and Qbtech, maintain significant North American commercial presences. Federal and state early intervention funding provides reliable reimbursement infrastructure.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding pediatric healthcare infrastructure and growing government commitment to neurodevelopmental screening programs. China and India are establishing national autism and developmental disability frameworks that create large-scale screening program requirements. Australia's National Disability Insurance Scheme funds early intervention services contingent on formal diagnosis, driving screening volume. Japan's comprehensive maternal and child health programs incorporate developmental assessments at multiple pediatric milestones. Increasing middle-class parental awareness of developmental conditions sustains strong private sector demand growth.

Key players in the market

Some of the key players in Neurodevelopmental Screening Technologies Market include Medtronic plc, Philips Healthcare, GE HealthCare, Siemens Healthineers AG, Roche Diagnostics, Cognoa, Inc., Qbtech AB, Pearson plc, Riverside Insights, BrainCheck Inc., Neurotech International, Natus Medical Incorporated, Canon Medical Systems, Fujifilm Holdings Corporation, IBM Corporation, Oracle Health, Epic Systems Corporation and Koninklijke KPN N.V..

Key Developments:

In June 2026, Cognoa, Inc. received FDA De Novo authorization for an expanded AI-powered autism screening algorithm validated across diverse pediatric demographic groups, enabling broader primary care deployment in community health settings.

In May 2026, Siemens Healthineers AG launched a next-generation neuroimaging analytics platform integrating deep learning algorithms for automated identification of neurodevelopmental biomarkers in pediatric MRI examinations.

In March 2026, Pearson plc released an updated digital version of its Bayley Scales of Infant and Toddler Development with automated scoring and normative comparison capabilities for clinical assessment workflows.

Screening Types Covered:

  • Autism Screening
  • ADHD Screening
  • Developmental Delay Screening
  • Language and Communication Assessment
  • Learning Disability Screening
  • Cognitive Function Screening

Components Covered:

  • Software
  • Hardware
  • Diagnostic Devices
  • Analytics Platforms
  • Services
  • Assessment Databases

Technologies Covered:

  • AI-Based Screening Platforms
  • Digital Assessment Tools
  • Neuroimaging Technologies
  • Behavioral Analytics Systems
  • Mobile Screening Applications
  • Cognitive Assessment Platforms
  • Telehealth Screening Technologies

Applications Covered:

  • Pediatric Healthcare
  • Educational Assessment
  • Early Intervention Programs
  • Research Studies
  • Community Health Screening
  • Telehealth Services
  • Clinical Diagnostics

End Users Covered:

  • Hospitals
  • Clinics
  • Educational Institutions
  • Research Centers
  • Government Agencies
  • Community Health Organizations

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Neurodevelopmental Screening Technologies Market, By Screening Type

  • 5.1 Autism Screening
  • 5.2 ADHD Screening
  • 5.3 Developmental Delay Screening
  • 5.4 Language and Communication Assessment
  • 5.5 Learning Disability Screening
  • 5.6 Cognitive Function Screening

6 Global Neurodevelopmental Screening Technologies Market, By Component

  • 6.1 Software
  • 6.2 Hardware
  • 6.3 Diagnostic Devices
  • 6.4 Analytics Platforms
  • 6.5 Services
  • 6.6 Assessment Databases

7 Global Neurodevelopmental Screening Technologies Market, By Technology

  • 7.1 AI-Based Screening Platforms
  • 7.2 Digital Assessment Tools
  • 7.3 Neuroimaging Technologies
  • 7.4 Behavioral Analytics Systems
  • 7.5 Mobile Screening Applications
  • 7.6 Cognitive Assessment Platforms
  • 7.7 Telehealth Screening Technologies

8 Global Neurodevelopmental Screening Technologies Market, By Application

  • 8.1 Pediatric Healthcare
  • 8.2 Educational Assessment
  • 8.3 Early Intervention Programs
  • 8.4 Research Studies
  • 8.5 Community Health Screening
  • 8.6 Telehealth Services
  • 8.7 Clinical Diagnostics

9 Global Neurodevelopmental Screening Technologies Market, By End User

  • 9.1 Hospitals
  • 9.2 Clinics
  • 9.3 Educational Institutions
  • 9.4 Research Centers
  • 9.5 Government Agencies
  • 9.6 Community Health Organizations

10 Global Neurodevelopmental Screening Technologies Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Medtronic plc
  • 13.2 Philips Healthcare
  • 13.3 GE HealthCare
  • 13.4 Siemens Healthineers AG
  • 13.5 Roche Diagnostics
  • 13.6 Cognoa, Inc.
  • 13.7 Qbtech AB
  • 13.8 Pearson plc
  • 13.9 Riverside Insights
  • 13.10 BrainCheck Inc.
  • 13.11 Neurotech International
  • 13.12 Natus Medical Incorporated
  • 13.13 Canon Medical Systems
  • 13.14 Fujifilm Holdings Corporation
  • 13.15 IBM Corporation
  • 13.16 Oracle Health
  • 13.17 Epic Systems Corporation
  • 13.18 Koninklijke KPN N.V.

List of Tables

  • Table 1 Global Neurodevelopmental Screening Technologies Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neurodevelopmental Screening Technologies Market Outlook, By Screening Type (2023-2034) ($MN)
  • Table 3 Global Neurodevelopmental Screening Technologies Market Outlook, By Autism Screening (2023-2034) ($MN)
  • Table 4 Global Neurodevelopmental Screening Technologies Market Outlook, By ADHD Screening (2023-2034) ($MN)
  • Table 5 Global Neurodevelopmental Screening Technologies Market Outlook, By Developmental Delay Screening (2023-2034) ($MN)
  • Table 6 Global Neurodevelopmental Screening Technologies Market Outlook, By Language and Communication Assessment (2023-2034) ($MN)
  • Table 7 Global Neurodevelopmental Screening Technologies Market Outlook, By Learning Disability Screening (2023-2034) ($MN)
  • Table 8 Global Neurodevelopmental Screening Technologies Market Outlook, By Cognitive Function Screening (2023-2034) ($MN)
  • Table 9 Global Neurodevelopmental Screening Technologies Market Outlook, By Component (2023-2034) ($MN)
  • Table 10 Global Neurodevelopmental Screening Technologies Market Outlook, By Software (2023-2034) ($MN)
  • Table 11 Global Neurodevelopmental Screening Technologies Market Outlook, By Hardware (2023-2034) ($MN)
  • Table 12 Global Neurodevelopmental Screening Technologies Market Outlook, By Diagnostic Devices (2023-2034) ($MN)
  • Table 13 Global Neurodevelopmental Screening Technologies Market Outlook, By Analytics Platforms (2023-2034) ($MN)
  • Table 14 Global Neurodevelopmental Screening Technologies Market Outlook, By Services (2023-2034) ($MN)
  • Table 15 Global Neurodevelopmental Screening Technologies Market Outlook, By Assessment Databases (2023-2034) ($MN)
  • Table 16 Global Neurodevelopmental Screening Technologies Market Outlook, By Technology (2023-2034) ($MN)
  • Table 17 Global Neurodevelopmental Screening Technologies Market Outlook, By AI-Based Screening Platforms (2023-2034) ($MN)
  • Table 18 Global Neurodevelopmental Screening Technologies Market Outlook, By Digital Assessment Tools (2023-2034) ($MN)
  • Table 19 Global Neurodevelopmental Screening Technologies Market Outlook, By Neuroimaging Technologies (2023-2034) ($MN)
  • Table 20 Global Neurodevelopmental Screening Technologies Market Outlook, By Behavioral Analytics Systems (2023-2034) ($MN)
  • Table 21 Global Neurodevelopmental Screening Technologies Market Outlook, By Mobile Screening Applications (2023-2034) ($MN)
  • Table 22 Global Neurodevelopmental Screening Technologies Market Outlook, By Cognitive Assessment Platforms (2023-2034) ($MN)
  • Table 23 Global Neurodevelopmental Screening Technologies Market Outlook, By Telehealth Screening Technologies (2023-2034) ($MN)
  • Table 24 Global Neurodevelopmental Screening Technologies Market Outlook, By Application (2023-2034) ($MN)
  • Table 25 Global Neurodevelopmental Screening Technologies Market Outlook, By Pediatric Healthcare (2023-2034) ($MN)
  • Table 26 Global Neurodevelopmental Screening Technologies Market Outlook, By Educational Assessment (2023-2034) ($MN)
  • Table 27 Global Neurodevelopmental Screening Technologies Market Outlook, By Early Intervention Programs (2023-2034) ($MN)
  • Table 28 Global Neurodevelopmental Screening Technologies Market Outlook, By Research Studies (2023-2034) ($MN)
  • Table 29 Global Neurodevelopmental Screening Technologies Market Outlook, By Community Health Screening (2023-2034) ($MN)
  • Table 30 Global Neurodevelopmental Screening Technologies Market Outlook, By Telehealth Services (2023-2034) ($MN)
  • Table 31 Global Neurodevelopmental Screening Technologies Market Outlook, By Clinical Diagnostics (2023-2034) ($MN)
  • Table 32 Global Neurodevelopmental Screening Technologies Market Outlook, By End User (2023-2034) ($MN)
  • Table 33 Global Neurodevelopmental Screening Technologies Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 34 Global Neurodevelopmental Screening Technologies Market Outlook, By Clinics (2023-2034) ($MN)
  • Table 35 Global Neurodevelopmental Screening Technologies Market Outlook, By Educational Institutions (2023-2034) ($MN)
  • Table 36 Global Neurodevelopmental Screening Technologies Market Outlook, By Research Centers (2023-2034) ($MN)
  • Table 37 Global Neurodevelopmental Screening Technologies Market Outlook, By Government Agencies (2023-2034) ($MN)
  • Table 38 Global Neurodevelopmental Screening Technologies Market Outlook, By Community Health Organizations (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.